RIPK3 acts as a lipid metabolism regulator contributing to inflammation and carcinogenesis in non-alcoholic fatty liver disease.

Marta B AfonsoPedro M RodriguesMiguel Mateus-PinheiroAndré L SimãoMaria M GasparAmine MajdiEnara ArretxeCristina AlonsoAlvaro Santos-LasoRaul Jimenez-AgüeroEmma EizaguirreLuis BujandaMaria Jesus ParejaJesus M BanalesVlad RatziuJeremie GautheronRui E CastroCecília Maria Pereira Rodrigues

Published in: Gut (2020)

Hepatic RIPK3 correlates with NAFLD severity in humans and mice, playing a key role in managing liver metabolism, damage, inflammation, fibrosis and carcinogenesis. Targeting RIPK3 and its intricate signalling arises as a novel promising approach to treat NASH and arrest disease progression.

Keyphrases

oxidative stress
liver fibrosis
transcription factor
cancer therapy
high fat diet induced
fatty acid
metabolic syndrome
type diabetes
cell proliferation
drug delivery
insulin resistance